Heart Failure Reviews

, Volume 12, Issue 2, pp 167–172 | Cite as

Newer mechanical devices in the management of acute heart failure



Heart Failure is the only cardiovascular disease diagnosis increasing in prevalence in the United States. Currently there are more than 5 million people diagnosed with heart failure in the United States and that population is increasing exponentially. Clinical trials in advanced pharmacological therapies have shown a significant value in reducing the morbidity and mortality of the disease process. Nevertheless, many patients who are optimally treated with drug therapy continue to progress from asymptomatic left ventricular dysfunction to symptomatic and then end-stage heart failure. Beyond drug therapy, devices have begun to make a significant impact on symptoms and clinical outcomes in patients, particularly those with more advanced forms of heart failure. New technologies being investigated include destination and bridge LV assist devices. Due to the invasive nature of these devices a new generation of “less invasive” percutaneous devices are now being studied. These new generation devices offer the promise of improved LV function and an enhanced neurohormonal profile for the failing ventricle, thus improving the quality of life in the ever-burgeoning heart failure population.


Acute heart failure Assist devices Ultrafiltration 


  1. 1.
    American Heart Association (2004) Heart disease and stroke statistics: 2004 update. American Heart Association, Dallas, TXGoogle Scholar
  2. 2.
    Berry C, Murdoch DR, McMurray JJ (2001) Economics of chronic heart failure. Eur J Heart Fail 3:283–291PubMedCrossRefGoogle Scholar
  3. 3.
    Aronow WS, Ahn C, Kronzon I, Koenigsberg M (1991) Congestive heart failure, coronary events and atherothrombotic brain infarction in elderly blacks and whites with systemic hypertension and with and without echocardiographic and electrocardiographic evidence of left ventricular hypertrophy. Am J Cardiol 67:295–299PubMedCrossRefGoogle Scholar
  4. 4.
    Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M (1991) A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325:303–310PubMedCrossRefGoogle Scholar
  5. 5.
    Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: U.S. carvedilol heart failure study group. N Engl J Med 334:1349–1355PubMedCrossRefGoogle Scholar
  6. 6.
    Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL (2001) Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651–1658PubMedCrossRefGoogle Scholar
  7. 7.
    Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309–1321PubMedCrossRefGoogle Scholar
  8. 8.
    Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, Djian J, Drexler H, Feldman A, Kober L, Krum H, Liu P, Nieminen M, Tavazzi L, Van Veldhuisen DJ, Waldenstrom A, Warren M, Westheim A, Zannad F, Flemming T (2004) Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109:1594–1602PubMedCrossRefGoogle Scholar
  9. 9.
    Mancini D, Burkhoff D (2005) Mechanical device-based methods of managing and treating heart failure. Circulation 112:438–448PubMedCrossRefGoogle Scholar
  10. 10.
    Costanzo MR (2006) Ultrafiltration versus IV diuretics for patients hospitalized for acute decompensated congestive heart failure: a prospective randomized clinical trial: UNLOAD. Presented at the American College of Cardiology annual scientific session, March 2006Google Scholar
  11. 11.
    Haithcock BE, Morita H, Fanous NH, Suzuki G, Sabbah HN (2004) Hemodynamic unloading of the failing left ventricle using an arterial-to-arterial extracorporeal flow circuit. Ann Thorac Surg 77:158–163PubMedCrossRefGoogle Scholar
  12. 12.
    Konstam MA, Czerska B, Bohm M, Oren RM, Sadowski J, Khanal S, Abraham WT, Wasler A, Dahm JB, Gavazzi A, Gradinac S, Legrand V, Mohacsi P, Poelzl G, Radovancevic B, Van Bakel AM, Zile MR, Cabua B, Bartus K, Jansen P (2005) Continuous aortic flow augmentation: hemodynamic and renal responses to a novel percutaneous intervention in patients with decompensated heart failure. Circulation 112:3107–3114PubMedCrossRefGoogle Scholar
  13. 13.
    Gharib M, Beizaie M (2003) Correlation between negative near-wall shear stress in human aorta and various stages of congestive heart failure. Ann Biomed Eng 3:678–685CrossRefGoogle Scholar
  14. 14.
    Thiele H, Lauer B, Hambrecht R, Boudriot E, Cohen HA, Schuler G (2001) Reversal of cardiogenic shock by percutaneous left atrial-to-femoral arterial bypass assistance. Circulation 104:2917–2922PubMedGoogle Scholar
  15. 15.
    LaRocca GM, Shimbo D, Rodriguez CJ, Stewart A, Naka Y, Weinberger J, Homma S, Pizzarello R (2006) The impella recover LP 5.0 left ventricular assist device: a bridge to coronary artery bypass grafting and cardiac transplantation. J Am Soc Echocardiogr Apr;19(4):468.e5–7Google Scholar
  16. 16.
    Henriques JP, Remmelink M, Baan J Jr, van der Schaaf RJ, Vis MM, Koch KT, Scholten EW, de Mol BA, Tijssen JG, Piek JJ, de Winter RJ (2006) Safety and feasibility of elective high-risk percutaneous coronary intervention procedures with left ventricular support of the Impella Recover LP 2.5. Am J Cardiol, Apr 1;97(7):990–992, Epub 2006 Feb 13Google Scholar
  17. 17.
    Registry. ABVW (1999) Courtesy of Abiomed IncGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  1. 1.Jefferson Medical College of Thomas Jefferson UniversityPhiladelphiaUSA
  2. 2.Tufts-New England Medical CenterBostonUSA
  3. 3.Jefferson Heart InstitutePhiladelphiaUSA

Personalised recommendations